Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLEX 404 Oral Liquid in MDS and CMML
NCT02944955Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Modality
- Botanical drug
01
Overview
Phase 2, open-label, single-arm trial of bli-1401 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Primary endpoints: Recommended Dose Level at 8 weeks and Incidence of Infections at 24 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
bli-1401
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02944955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944955.